173 related articles for article (PubMed ID: 12960698)
1. PTEN protein expression correlates with PTEN gene molecular changes but not with VEGF expression in astrocytomas.
Idoate MA; Soria E; Lozano MD; Sola JJ; Panizo A; de Alava E; Manrique M; Pardo-Mindán FJ
Diagn Mol Pathol; 2003 Sep; 12(3):160-5. PubMed ID: 12960698
[TBL] [Abstract][Full Text] [Related]
2. Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas.
Cheng Y; Pang JC; Ng HK; Ding M; Zhang SF; Zheng J; Liu DG; Poon WS
Histopathology; 2000 Nov; 37(5):437-44. PubMed ID: 11119125
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations in pediatric high-grade astrocytomas.
Cheng Y; Ng HK; Zhang SF; Ding M; Pang JC; Zheng J; Poon WS
Hum Pathol; 1999 Nov; 30(11):1284-90. PubMed ID: 10571506
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.
Fujisawa H; Kurrer M; Reis RM; Yonekawa Y; Kleihues P; Ohgaki H
Am J Pathol; 1999 Aug; 155(2):387-94. PubMed ID: 10433932
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemical mapping of the phosphatase and tensin homolog (PTEN/MMAC1) tumor suppressor protein in human gliomas.
Fults D; Pedone C
Neuro Oncol; 2000 Apr; 2(2):71-9. PubMed ID: 11303623
[TBL] [Abstract][Full Text] [Related]
6. p53 and PTEN gene mutations in gemistocytic astrocytomas.
Watanabe K; Peraud A; Gratas C; Wakai S; Kleihues P; Ohgaki H
Acta Neuropathol; 1998 Jun; 95(6):559-64. PubMed ID: 9650746
[TBL] [Abstract][Full Text] [Related]
7. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of molecular alterations in microdissected archival gliomas.
Walker C; Joyce KA; Thompson-Hehir J; Davies MP; Gibbs FE; Halliwell N; Lloyd BH; Machell Y; Roebuck MM; Salisbury J; Sibson DR; Du Plessis D; Broome J; Rossi ML
Acta Neuropathol; 2001 Apr; 101(4):321-33. PubMed ID: 11355303
[TBL] [Abstract][Full Text] [Related]
9. High-throughput molecular profiling of high-grade astrocytomas: the utility of fluorescence in situ hybridization on tissue microarrays (TMA-FISH).
Fuller CE; Wang H; Zhang W; Fuller GN; Perry A
J Neuropathol Exp Neurol; 2002 Dec; 61(12):1078-84. PubMed ID: 12484570
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathogenesis of malignant gliomas.
Rasheed BK; Wiltshire RN; Bigner SH; Bigner DD
Curr Opin Oncol; 1999 May; 11(3):162-7. PubMed ID: 10328589
[TBL] [Abstract][Full Text] [Related]
11. PTEN, DMBT1, and p16 alterations in diffusely infiltrating astrocytomas.
Fan X; Muñoz J; Sanko SG; Castresana JS
Int J Oncol; 2002 Sep; 21(3):667-74. PubMed ID: 12168116
[TBL] [Abstract][Full Text] [Related]
12. Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas.
Maier D; Zhang Z; Taylor E; Hamou MF; Gratzl O; Van Meir EG; Scott RJ; Merlo A
Oncogene; 1998 Jun; 16(25):3331-5. PubMed ID: 9681833
[TBL] [Abstract][Full Text] [Related]
13. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts.
Schmidt EE; Ichimura K; Goike HM; Moshref A; Liu L; Collins VP
J Neuropathol Exp Neurol; 1999 Nov; 58(11):1170-83. PubMed ID: 10560660
[TBL] [Abstract][Full Text] [Related]
14. Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation.
Mott RT; Turner KC; Bigner DD; McLendon RE
J Neurosurg; 2008 Feb; 108(2):330-5. PubMed ID: 18240930
[TBL] [Abstract][Full Text] [Related]
15. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
Tohma Y; Gratas C; Biernat W; Peraud A; Fukuda M; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1998 Jul; 57(7):684-9. PubMed ID: 9690672
[TBL] [Abstract][Full Text] [Related]
16. Presence of allelic loss and PTEN mutations in malignant gliomas from Malay patients.
Zainuddin N; Jaafar H; Isa MN; Abdullah JM
Med J Malaysia; 2004 Oct; 59(4):468-79. PubMed ID: 15779579
[TBL] [Abstract][Full Text] [Related]
17. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG
Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations.
Zhou XP; Li YJ; Hoang-Xuan K; Laurent-Puig P; Mokhtari K; Longy M; Sanson M; Delattre JY; Thomas G; Hamelin R
Int J Cancer; 1999 Apr; 84(2):150-4. PubMed ID: 10096247
[TBL] [Abstract][Full Text] [Related]
19. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
[TBL] [Abstract][Full Text] [Related]
20. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma.
Chan AS; Leung SY; Wong MP; Yuen ST; Cheung N; Fan YW; Chung LP
Am J Surg Pathol; 1998 Jul; 22(7):816-26. PubMed ID: 9669344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
